These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Martelli AM; Evangelisti C; Chiarini F; McCubrey JA Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809 [TBL] [Abstract][Full Text] [Related]
7. Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. Nepstad I; Reikvam H; Brenner AK; Bruserud Ø; Hatfield KJ Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382066 [TBL] [Abstract][Full Text] [Related]
8. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. Nepstad I; Hatfield KJ; Aasebø E; Hernandez-Valladares M; Brenner AK; Bartaula-Brevik S; Berven F; Selheim F; Skavland J; Gjertsen BT; Reikvam H; Bruserud Ø Expert Opin Ther Targets; 2018 Jul; 22(7):639-653. PubMed ID: 29889583 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Reikvam H; Nepstad I; Bruserud Ø; Hatfield KJ Oncotarget; 2013 Jun; 4(6):830-43. PubMed ID: 23919981 [TBL] [Abstract][Full Text] [Related]
10. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943 [TBL] [Abstract][Full Text] [Related]
11. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Nepstad I; Hatfield KJ; Grønningsæter IS; Reikvam H Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326335 [TBL] [Abstract][Full Text] [Related]
12. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685 [TBL] [Abstract][Full Text] [Related]
14. CXCL8 derived from mesenchymal stromal cells supports survival and proliferation of acute myeloid leukemia cells through the PI3K/AKT pathway. Cheng J; Li Y; Liu S; Jiang Y; Ma J; Wan L; Li Q; Pang T FASEB J; 2019 Apr; 33(4):4755-4764. PubMed ID: 30592634 [TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer. Sathe A; Nawroth R Methods Mol Biol; 2018; 1655():335-350. PubMed ID: 28889395 [TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625 [TBL] [Abstract][Full Text] [Related]
17. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104 [TBL] [Abstract][Full Text] [Related]
18. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo. Zou Y; Ge M; Wang X Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128 [TBL] [Abstract][Full Text] [Related]
19. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo. Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447 [TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells. Liang H; Zheng QL; Fang P; Zhang J; Zhang T; Liu W; Guo M; Robinson CL; Chen SB; Chen XP; Chen FP; Zeng H Sci Rep; 2017 Jan; 7():40361. PubMed ID: 28098170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]